Background
Anivovetmab (KIND-030) is an anti-VP2 (parvovirus major capsid protein) monoclonal antibody (IgG2 type). Anivovetmab has the potential to study canine parvovirus infection.• Identification of Potential Novel B-Cell Epitopes of Capsid Protein VP2 in Senecavirus A., PMID:37428080• The VP2 protein exhibits cross-interaction to the VP1 protein in norovirus GII.17., PMID:35272046• The first report of porcine parvovirus 7 (PPV7) in Colombia demonstrates the presence of variants associated with modifications at the level of the VP2-capsid protein., PMID:34914702• Capsid assembly is regulated by amino acid residues asparagine 47 and 48 in the VP2 protein of porcine parvovirus., PMID:33433338• Norwalk Virus Minor Capsid Protein VP2 Associates within the VP1 Shell Domain., PMID:23408637• Foot-and-mouth disease virus capsid protein VP2 activates the cellular EIF2S1-ATF4 pathway and induces autophagy via HSPB1., PMID:29166823• Soluble overexpression and purification of infectious bursal disease virus capsid protein VP2 inEscherichia coliand its nanometer structure observation., PMID:35343377• Interaction between Bluetongue virus outer capsid protein VP2 and vimentin is necessary for virus egress., PMID:17224050• Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus., PMID:15163751• Feline calicivirus VP2 is involved in the self-assembly of the capsid protein into virus-like particles., PMID:20362313